v3.25.2
Significant Agreements - Bristol Myers Squibb Collaboration Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
May 24, 2024
Jul. 05, 2023
Jul. 30, 2021
Mar. 20, 2018
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Mar. 31, 2025
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Deferred revenue, current         $ 5,100   $ 5,100     $ 8,850
Collaboration revenue         4,420 $ 132,014 7,248 $ 132,064    
Deferred revenue, non-current         0   0     3,448
Collaboration Program, US Rights | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Expected Allocation of initial Transaction Price       $ 15,000            
Collaboration Program, US Rights | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Expected Allocation of initial Transaction Price       25,000            
Collaboration Program, Global Rights                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Potential Regulatory Milestone Payments per Program       187,500            
Collaboration Agreement, Potential Commercial Sale Milestone Payments       375,000            
Collaboration Program, Global Rights | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Expected Allocation of initial Transaction Price       10,000            
Collaboration Program, Global Rights | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Expected Allocation of initial Transaction Price       18,000            
Collaboration revenue                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration revenue         4,420 132,014 7,198 132,014    
Bristol Myers Squibb                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments per Program       562,500            
Collaboration revenue         4,400 $ 132,000 7,200 $ 132,000    
Deferred Revenue         5,100   5,100   $ 9,500  
Bristol Myers Squibb | Collaboration Program, US Rights                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Exercise fee per Program       80,000            
Bristol Myers Squibb | Collaboration Program, Global Rights                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Exercise fee per Program       55,000            
Bristol Myers Squibb | Collaboration Program, US, tau/ BMS-986446                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Program, US License Agreement, Upfront Payment     $ 80,000              
Bristol Myers Squibb | Collaboration Program, Global, tau/ BMS-986446                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Potential Regulatory and Commercial Milestone Payments per Program   $ 562,500                
Collaboration Agreement, Allocation of Initial Transaction Price   17,900                
Collaboration program, Global Exercise Fee   55,000                
Collaboration Agreement, Total Transaction Price, PRX005 Global   $ 72,900                
Bristol Myers Squibb | Collaboration Program, Global, PRX019                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Potential Commercial Sale Milestone Payments $ 375,000                  
Collaboration revenue         4,400          
Collaboration Agreement, Allocation of Initial Transaction Price       17,400            
Allocated consideration to performance obligations 106,300                  
Collaboration program, Global Exercise Fee 80,000                  
Collaboration Agreement, Potential Development and Regulatory Milestone Payments $ 242,500                  
BMS (formerly Celgene)                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Upfront Payment       $ 100,000            
Collaboration Agreement, Option fees and Milestone payments, Payment Term       30 days            
BMS (formerly Celgene) | Private Placement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Share Subscription Agreement, Number of ordinary shares issued in transaction (in shares)       1,174,536            
Share Subscription Agreement, Price per share (in dollars per share)       $ 42.57            
Share Subscription Agreement, Consideration received on transaction       $ 50,000            
Share Subscription Agreement, Premium received on transaction       10,200            
Collaborative Arrangement | Bristol Myers Squibb                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Accounts receivable         0   0     $ 0
Revenue, Remaining performance obligation, Amount         $ 5,100   $ 5,100      
Collaborative Arrangement | BMS (formerly Celgene)                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Collaboration Agreement, Initial Transaction Price       $ 110,200